GLIADEL

LOE Approaching

carmustine

NDAINTRACRANIALIMPLANTPriority Review
Approved
Sep 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13

Mechanism of Action

Alkylating Activity

Pharmacologic Class:

Alkylating Drug

Clinical Trials (5)

NCT05083754Phase 1Recruiting

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

Started Aug 2022
50 enrolled
Glioblastoma Multiforme
NCT02300506N/ACompleted

Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma

Started Jan 2014
507 enrolled
Malignant Glioma
NCT02300532N/ACompleted

Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)

Started Jan 2013
561 enrolled
Malignant Glioma
NCT01186406Phase 2Terminated

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

Started Apr 2011
41 enrolled
Glioblastoma MultiformeGliosarcoma
NCT00984438Phase 1/2Withdrawn

Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme

Started Jun 2009
0
Glioblastoma Multiforme